company background image
GOV logo

Insulet DB:GOV Stock Report

Last Price

€282.60

Market Cap

€19.9b

7D

24.2%

1Y

78.1%

Updated

13 May, 2025

Data

Company Financials +

Insulet Corporation

DB:GOV Stock Report

Market Cap: €19.9b

GOV Stock Overview

Develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. More details

GOV fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 10.69% per year

Earnings grew by 71.9% over the past year

Risk Analysis

Volatile share price over the past 3 months compared to the German market


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Insulet Corporation Competitors

Siemens Healthineers

XTRA:SHL

€54.5b

Carl Zeiss Meditec

XTRA:AFX

€5.5b

Eckert & Ziegler

XTRA:EUZ

€1.2b

Drägerwerk KGaA

XTRA:DRW3

€1.0b

Price History & Performance

Summary of share price highs, lows and changes for Insulet
Historical stock prices
Current Share PriceUS$282.60
52 Week HighUS$288.00
52 Week LowUS$147.20
Beta1.27
1 Month Change26.27%
3 Month Change4.82%
1 Year Change78.07%
3 Year Change49.16%
5 Year Change56.13%
Change since IPO2,368.12%

Recent News & Updates

Recent updates

Shareholder Returns

GOVDE Medical EquipmentDE Market
7D24.2%1.7%0.7%
1Y78.1%-9.4%13.8%

Return vs Industry: GOV exceeded the German Medical Equipment industry which returned -9.4% over the past year.

Return vs Market: GOV exceeded the German Market which returned 13.8% over the past year.

Price Volatility

Is GOV's price volatile compared to industry and market?
GOV volatility
GOV Average Weekly Movement8.7%
Medical Equipment Industry Average Movement5.9%
Market Average Movement6.4%
10% most volatile stocks in DE Market12.9%
10% least volatile stocks in DE Market3.1%

Stable Share Price: GOV's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: GOV's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20003,900Ashley McEvoywww.insulet.com

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.

Insulet Corporation Fundamentals Summary

How do Insulet's earnings and revenue compare to its market cap?
GOV fundamental statistics
Market cap€19.91b
Earnings (TTM)€359.41m
Revenue (TTM)€1.96b

55.0x

P/E Ratio

10.1x

P/S Ratio

Is GOV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GOV income statement (TTM)
RevenueUS$2.20b
Cost of RevenueUS$651.00m
Gross ProfitUS$1.55b
Other ExpensesUS$1.15b
EarningsUS$402.20m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)5.72
Gross Margin70.39%
Net Profit Margin18.29%
Debt/Equity Ratio127.4%

How did GOV perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/13 23:41
End of Day Share Price 2025/05/13 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Insulet Corporation is covered by 59 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anand VankawalaAvondale Partners
null nullBaird
Jeffrey JohnsonBaird